Skip to main content

Articles

Page 1 of 100

  1. The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (...

    Authors: Evelien Schaafsma, Baoyi Zhang, Merit Schaafsma, Chun-Yip Tong, Lanjing Zhang and Chao Cheng

    Citation: Breast Cancer Research 2021 23:74

    Content type: Research article

    Published on:

  2. The acquisition of oncogenic drivers is a critical feature of cancer progression. For some carcinomas, it is clear that certain genetic drivers occur early in neoplasia and others late. Why these drivers are s...

    Authors: Peipei Lu, Joseph Foley, Chunfang Zhu, Katherine McNamara, Korsuk Sirinukunwattana, Sujay Vennam, Sushama Varma, Hamid Fehri, Arunima Srivastava, Shirley Zhu, Jens Rittscher, Parag Mallick, Christina Curtis and Robert West

    Citation: Breast Cancer Research 2021 23:73

    Content type: Research article

    Published on:

  3. Re-excision due to positive margins following breast-conserving surgery (BCS) negatively affects patient outcomes and healthcare costs. The inability to visualize margin involvement is a significant challenge ...

    Authors: Kathryn Ottolino-Perry, Anam Shahid, Stephanie DeLuca, Viktor Son, Mayleen Sukhram, Fannong Meng, Zhihui ( Amy) Liu, Sara Rapic, Nayana Thalanki Anantha, Shirley C. Wang, Emilie Chamma, Christopher Gibson, Philip J. Medeiros, Safa Majeed, Ashley Chu, Olivia Wignall…

    Citation: Breast Cancer Research 2021 23:72

    Content type: Research article

    Published on:

  4. Adolescence and early adulthood has been identified as a critical time window for establishing breast cancer risk. Mammographic density is an independent risk factor for breast cancer that may be influenced by...

    Authors: Nichole A. Garzia, Kara Cushing-Haugen, Thomas W. Kensler, Rulla M. Tamimi and Holly R. Harris

    Citation: Breast Cancer Research 2021 23:71

    Content type: Research article

    Published on:

  5. We investigated the associations of reproductive factors with the percentage of epithelium, stroma, and fat tissue in benign breast biopsy samples.

    Authors: Lusine Yaghjyan, Rebecca J. Austin-Datta, Hannah Oh, Yujing J. Heng, Adithya D. Vellal, Korsuk Sirinukunwattana, Gabrielle M. Baker, Laura C. Collins, Divya Murthy, Bernard Rosner and Rulla M. Tamimi

    Citation: Breast Cancer Research 2021 23:70

    Content type: Research article

    Published on:

  6. Heterogeneity within the mouse mammary epithelium and potential lineage relationships have been recently explored by single-cell RNA profiling. To further understand how cellular diversity changes during mamma...

    Authors: Bhupinder Pal, Yunshun Chen, Michael J. G. Milevskiy, François Vaillant, Lexie Prokopuk, Caleb A. Dawson, Bianca D. Capaldo, Xiaoyu Song, Felicity Jackling, Paul Timpson, Geoffrey J. Lindeman, Gordon K. Smyth and Jane E. Visvader

    Citation: Breast Cancer Research 2021 23:69

    Content type: Research article

    Published on:

  7. Few studies have investigated risk factor heterogeneity by molecular subtypes in indigenous African populations where prevalence of traditional breast cancer (BC) risk factors, genetic background, and environm...

    Authors: Shahin Sayed, Shaoqi Fan, Zahir Moloo, Ronald Wasike, Peter Bird, Mansoor Saleh, Asim Jamal Shaikh, Jonine D. Figueroa, Richard Naidoo, Francis W. Makokha, Kevin Gardner, Raymond Oigara, Faith Wambui Njoroge, Pumza Magangane, Miriam Mutebi, Rajendra Chauhan…

    Citation: Breast Cancer Research 2021 23:68

    Content type: Research article

    Published on:

  8. Normal human breast tissues are a heterogeneous mix of epithelial and stromal subtypes in different cell states. Delineating the spectrum of cellular heterogeneity will provide new insights into normal cellula...

    Authors: Siru Virtanen, Reiner Schulte, John Stingl, Carlos Caldas and Mona Shehata

    Citation: Breast Cancer Research 2021 23:66

    Content type: Research article

    Published on:

  9. Breast cancer (BC) is the most common cancer in women and the leading cause of cancer-associated mortality in women. In particular, triple-negative BC (TNBC) has the highest rate of mortality due in large part...

    Authors: Katie A. Thies, Matthew W. Cole, Rachel E. Schafer, Jonathan M. Spehar, Dillon S. Richardson, Sarah A. Steck, Manjusri Das, Arthur W. Lian, Alo Ray, Reena Shakya, Sue E. Knoblaugh, Cynthia D. Timmers, Michael C. Ostrowski, Arnab Chakravarti, Gina M. Sizemore and Steven T. Sizemore

    Citation: Breast Cancer Research 2021 23:65

    Content type: Research article

    Published on:

  10. Advanced breast cancer (BC) impact immune cells in the blood but whether such effects may reflect the presence of early BC and its therapeutic management remains elusive.

    Authors: Sarah Cattin, Benoît Fellay, Antonello Calderoni, Alexandre Christinat, Laura Negretti, Maira Biggiogero, Alberto Badellino, Anne-Lise Schneider, Pelagia Tsoutsou, Alessandra Franzetti Pellanda and Curzio Rüegg

    Citation: Breast Cancer Research 2021 23:64

    Content type: Research article

    Published on:

  11. Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades. While clinical latency has been postulated to reflect the...

    Authors: Jason R. Ruth, Dhruv K. Pant, Tien-chi Pan, Hans E. Seidel, Sanjeethan C. Baksh, Blaine A. Keister, Rita Singh, Christopher J. Sterner, Suzanne J. Bakewell, Susan E. Moody, George K. Belka and Lewis A. Chodosh

    Citation: Breast Cancer Research 2021 23:63

    Content type: Research article

    Published on:

  12. In contrast to developed countries, breast cancer in China is characterized by a rapidly escalating incidence rate in the past two decades, lower survival rate, and vast geographic variation. However, there is...

    Authors: Yuting Han, Jun Lv, Canqing Yu, Yu Guo, Zheng Bian, Yizhen Hu, Ling Yang, Yiping Chen, Huaidong Du, Fangyuan Zhao, Wanqing Wen, Xiao-Ou Shu, Yongbing Xiang, Yu-Tang Gao, Wei Zheng, Hong Guo…

    Citation: Breast Cancer Research 2021 23:62

    Content type: Research article

    Published on:

  13. The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induc...

    Authors: Victor Sarradin, Amélie Lusque, Thomas Filleron, Florence Dalenc and Camille Franchet

    Citation: Breast Cancer Research 2021 23:61

    Content type: Research article

    Published on:

  14. Although the incidence of positive resection margins in breast-conserving surgery has decreased, both incomplete resection and unnecessary large resections still occur. This is especially the case in the surgi...

    Authors: Lisanne L. de Boer, Esther Kho, Koen K. Van de Vijver, Marie-Jeanne T. F. D. Vranken Peeters, Frederieke van Duijnhoven, Benno H. W. Hendriks, Henricus J. C. M. Sterenborg and Theo J. M. Ruers

    Citation: Breast Cancer Research 2021 23:59

    Content type: Research article

    Published on:

  15. DNA methylation alterations have similar patterns in normal aging tissue and in cancer. In this study, we investigated breast tissue-specific age-related DNA methylation alterations and used those methylation ...

    Authors: Shoghag Panjarian, Jozef Madzo, Kelsey Keith, Carolyn M. Slater, Carmen Sapienza, Jaroslav Jelinek and Jean-Pierre J. Issa

    Citation: Breast Cancer Research 2021 23:58

    Content type: Research article

    Published on:

  16. Endocrine therapies targeting estrogen signaling have significantly improved breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to those therapies. Aside from genomic signalin...

    Authors: Julien Jacquemetton, Loay Kassem, Coralie Poulard, Ahmed Dahmani, Ludmilla De Plater, Elodie Montaudon, Laura Sourd, Ludivine Morisset, Rania El Botty, Sophie Chateau-Joubert, Sophie Vacher, Ivan Bièche, Isabelle Treilleux, Olivier Trédan, Elisabetta Marangoni and Muriel Le Romancer

    Citation: Breast Cancer Research 2021 23:57

    Content type: Research article

    Published on:

  17. Invasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from > 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proi...

    Authors: Simion C. Dinca, Daniel Greiner, Keren Weidenfeld, Laura Bond, Dalit Barkan and Cheryl L. Jorcyk

    Citation: Breast Cancer Research 2021 23:56

    Content type: Research article

    Published on:

  18. Approximately 5–10% of HER2-positive breast cancers can be defined by low expression of the Ste20-like kinase, SLK, and high expression of SOX10. Our lab has observed that genetic deletion of SLK results in the i...

    Authors: Khalid N. Al-Zahrani, John Abou-Hamad, Julia Pascoal, Cédrik Labrèche, Brennan Garland and Luc A. Sabourin

    Citation: Breast Cancer Research 2021 23:55

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:60

  19. Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine ...

    Authors: Muriel Lainé, Sean W. Fanning, Ya-Fang Chang, Bradley Green, Marianne E. Greene, Barry Komm, Justyna D. Kurleto, Linda Phung and Geoffrey L. Greene

    Citation: Breast Cancer Research 2021 23:54

    Content type: Research article

    Published on:

  20. Biglycan is a proteoglycan found in the extracellular matrix. We have previously shown that biglycan is secreted from tumor endothelial cells and induces tumor angiogenesis and metastasis. However, the functio...

    Authors: Li Cong, Nako Maishi, Dorcas A. Annan, Marian F. Young, Hirofumi Morimoto, Masahiro Morimoto, Jin-Min Nam, Yasuhiro Hida and Kyoko Hida

    Citation: Breast Cancer Research 2021 23:51

    Content type: Research article

    Published on:

  21. We identified a rare missense germline mutation in BARD1 (c.403G>A or p.Asp135Asn) as pathogenic using integrated genomics and transcriptomics profiling of germline and tumor samples from an early-onset triple-ne...

    Authors: Yuanting Zheng, Bingying Li, Dejing Pan, Jun Cao, Jian Zhang, Xiaolin Wang, Xiangnan Li, Wanwan Hou, Ding Bao, Luyao Ren, Jingcheng Yang, Shangzi Wang, Yangyang Qiu, Fei Zhou, Zhiwei Liu, Sibo Zhu…

    Citation: Breast Cancer Research 2021 23:53

    Content type: Short report

    Published on:

  22. Early prediction of tumor response to neoadjuvant chemotherapy (NACT) is crucial for optimal treatment and improved outcome in breast cancer patients. The purpose of this study is to investigate the role of sh...

    Authors: Juanjuan Gu, Eric C. Polley, Max Denis, Jodi M. Carter, Sandhya Pruthi, Adriana V. Gregory, Judy C. Boughey, Robert T. Fazzio, Mostafa Fatemi and Azra Alizad

    Citation: Breast Cancer Research 2021 23:52

    Content type: Research article

    Published on:

  23. Authors: Antonella Ciabattoni, Fabiana Gregucci, Gerd Fastner, Silvio Cavuto, Antonio Spera, Stefano Drago, Ingrid Ziegler, Maria Alessandra Mirri, Rita Consorti and Felix Sedlmayer

    Citation: Breast Cancer Research 2021 23:50

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:46

  24. Mammographic breast density (MBD) and benign breast disease (BBD) are two of the strongest risk factors for breast cancer. Understanding trends in MBD by age and parity in women with BBD is essential to the cl...

    Authors: Laura L. Reimers, Mandy Goldberg, Parisa Tehranifar, Karin B. Michels, Barbara A. Cohn, Julie D. Flom, Ying Wei, Piera Cirillo and Mary Beth Terry

    Citation: Breast Cancer Research 2021 23:49

    Content type: Research article

    Published on:

  25. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Gerardo Gatti, Courtney Betts, Darío Rocha, Maribel Nicola, Verónica Grupe, Cecilia Ditada, Nicolas G. Nuñez, Emiliano Roselli, Paula Araya, Jeremías Dutto, Lucia Boffelli, Elmer Fernández, Lisa M. Coussens and Mariana Maccioni

    Citation: Breast Cancer Research 2021 23:48

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:40

  26. Menopausal hormone therapy (MHT) is a risk factor for breast cancer (BC). Evidence suggests that its effect on BC risk could be partly mediated by mammographic density. The aim of this study was to investigate...

    Authors: M. Fornili, V. Perduca, A. Fournier, A. Jérolon, M. C. Boutron-Ruault, G. Maskarinec, G. Severi and L. Baglietto

    Citation: Breast Cancer Research 2021 23:47

    Content type: Research article

    Published on:

  27. Intraoperative radiotherapy with electrons (IOERT) boost could be not inferior to external beam radiotherapy (EBRT) boost in terms of local control and tissue tolerance. The aim of the study is to present the ...

    Authors: Antonella Ciabattoni, Fabiana Gregucci, Gerd Fastner, Silvio Cavuto, Antonio Spera, Stefano Drago, Ingrid Ziegler, Maria Alessandra Mirri, Rita Consorti and Felix Sedlmayer

    Citation: Breast Cancer Research 2021 23:46

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:50

  28. An abundance of tumor-associated macrophages has been shown to be an independent prognostic factor for a poor prognosis of human breast cancer (BC). Adipose tissue accounts for the largest proportion of the br...

    Authors: Lili Lin, Christina Kuhn, Nina Ditsch, Thomas Kolben, Bastian Czogalla, Susanne Beyer, Fabian Trillsch, Elisa Schmoeckel, Doris Mayr, Sven Mahner, Udo Jeschke and Anna Hester

    Citation: Breast Cancer Research 2021 23:45

    Content type: Research article

    Published on:

  29. The epidemiologic evidence from observational studies on breast cancer risk and phthalates, endocrine disrupting chemicals, has been inconsistent. In the only previous study based on pre-diagnostic urinary pht...

    Authors: Anna H. Wu, Adrian A. Franke, Lynne R. Wilkens, Chiuchen Tseng, Shannon M. Conroy, Yuqing Li, Linda M. Polfus, Mindy De Rouen, Christian Caberto, Christopher Haiman, Daniel O. Stram, Loïc Le Marchand and Iona Cheng

    Citation: Breast Cancer Research 2021 23:44

    Content type: Research article

    Published on:

  30. Intraoperative radiotherapy (IORT) is more convenient than standard whole breast external beam radiotherapy (EBRT) as a sole adjuvant radiotherapy for breast cancer. The impact of age on breast cancer course a...

    Authors: Hsin-Yi Yang, Chi-Wen Tu, Chien-Chin Chen, Cheng-Yen Lee and Yu-Chen Hsu

    Citation: Breast Cancer Research 2021 23:43

    Content type: Research article

    Published on:

  31. Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance re...

    Authors: Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha…

    Citation: Breast Cancer Research 2021 23:42

    Content type: Research article

    Published on:

  32. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland III, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu…

    Citation: Breast Cancer Research 2021 23:41

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2017 19:130

  33. Characterization of breast cancer (BC) through the determination of conventional markers such as ER, PR, HER2, and Ki67 has been useful as a predictive and therapeutic tool. Also, assessment of tumor-infiltrat...

    Authors: Gerardo Gatti, Courtney Betts, Darío Rocha, Maribel Nicola, Verónica Grupe, Cecilia Ditada, Nicolas G. Nuñez, Emiliano Roselli, Paula Araya, Jeremías Dutto, Lucia Boffelli, Elmer Fernández, Lisa M. Coussens and Mariana Maccioni

    Citation: Breast Cancer Research 2021 23:40

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:48

  34. Transforming growth factor beta1 (TGFB1) is a multi-functional cytokine that regulates mammary gland development and cancer progression through endocrine, paracrine and autocrine mechanisms. TGFB1 also plays r...

    Authors: Xuan Sun, Sarah M. Bernhardt, Danielle J. Glynn, Leigh J. Hodson, Lucy Woolford, Andreas Evdokiou, Cong Yan, Hong Du, Sarah A. Robertson and Wendy V. Ingman

    Citation: Breast Cancer Research 2021 23:39

    Content type: Research article

    Published on:

  35. Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC ...

    Authors: Francesca Galardi, Francesca De Luca, Chiara Biagioni, Ilenia Migliaccio, Giuseppe Curigliano, Alessandro M. Minisini, Martina Bonechi, Erica Moretti, Emanuela Risi, Amelia McCartney, Matteo Benelli, Dario Romagnoli, Silvia Cappadona, Stefano Gabellini, Cristina Guarducci, Valerio Conti…

    Citation: Breast Cancer Research 2021 23:38

    Content type: Research article

    Published on:

  36. Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versu...

    Authors: Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo and Richard S. Finn

    Citation: Breast Cancer Research 2021 23:37

    Content type: Research article

    Published on:

  37. Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes.

    Authors: Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Christopher Herzog, Lale Umutlu, Alex Frydrychowicz, Dorothea Rjosk-Dendorfer, Rachel Würstlein, Ralph Culemann, Christine Eulenburg, Jascha Adams, Henrik Nitzsche, Anna Prange, Sherko Kümmel, Eva-Maria Grischke…

    Citation: Breast Cancer Research 2021 23:36

    Content type: Research article

    Published on:

  38. Brain metastasis of breast cancer exhibits exceedingly poor prognosis, and both triple negative (TN) and Her2+ subtypes have the highest incidence of brain metastasis. Although estrogen blockers are considered to...

    Authors: Shih-Ying Wu, Sambad Sharma, Kerui Wu, Abhishek Tyagi, Dan Zhao, Ravindra Pramod Deshpande and Kounosuke Watabe

    Citation: Breast Cancer Research 2021 23:35

    Content type: Research article

    Published on:

  39. Among women diagnosed with invasive breast cancer, 30% have a prior diagnosis of benign breast disease (BBD). Thus, it is important to identify factors among BBD patients that elevate invasive cancer risk. In ...

    Authors: Jonine D. Figueroa, Gretchen L. Gierach, Máire A. Duggan, Shaoqi Fan, Ruth M. Pfeiffer, Yihong Wang, Roni T. Falk, Olivier Loudig, Mustapha Abubakar, Mindy Ginsberg, Teresa M. Kimes, Kathryn Richert-Boe, Andrew G. Glass and Thomas E. Rohan

    Citation: Breast Cancer Research 2021 23:34

    Content type: Research article

    Published on:

  40. The recommended starting dose of eribulin in patients with hepatic impairment is based on the Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in...

    Authors: Iain R. Macpherson, Yaohua He and Carlo Palmieri

    Citation: Breast Cancer Research 2021 23:33

    Content type: Research article

    Published on:

  41. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves

    Citation: Breast Cancer Research 2021 23:32

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:25

  42. Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor...

    Authors: Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon and François-Clément Bidard

    Citation: Breast Cancer Research 2021 23:31

    Content type: Research article

    Published on:

  43. Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclin...

    Authors: Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres and Eddy S. Yang

    Citation: Breast Cancer Research 2021 23:30

    Content type: Research article

    Published on:

  44. MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with c...

    Authors: Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava…

    Citation: Breast Cancer Research 2021 23:29

    Content type: Research article

    Published on:

  45. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Mattias Aine, Ceren Boyaci, Johan Hartman, Jari Häkkinen, Shamik Mitra, Ana Bosch Campos, Emma Nimeus, Anna Ehinger, Johan Vallon-Christersson, Åke Borg and Johan Staaf

    Citation: Breast Cancer Research 2021 23:28

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2021 23:20

  46. Patients diagnosed with metastatic breast cancer have poor outcome with a median survival of approximately 2 years. While novel therapeutic options are urgently needed, the great majority of breast cancer rese...

    Authors: Jenny Stenström, Ingrid Hedenfalk and Catharina Hagerling

    Citation: Breast Cancer Research 2021 23:27

    Content type: Research article

    Published on:

  47. Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lack...

    Authors: Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch…

    Citation: Breast Cancer Research 2021 23:26

    Content type: Research article

    Published on:

  48. Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of D...

    Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle and André A. Neves

    Citation: Breast Cancer Research 2021 23:25

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2021 23:32

Annual Journal Metrics